In the first-line setting of metastatic NSCLC, the KEYNOTE-024 trial was the first phase 3 clinical trial that demonstrated an improvement in mOS in patients whose tumour expressed PD-L1 >50% [8]. Here, CD274 is linked to neoplasm.